Sevelamer Carbonate In vitro binding study for EMA submission [Regulatives / Guidelines]

posted by jansari – India, 2021-09-24 19:03 (244 d 20:11 ago) – Posting: # 22597
Views: 799

(edited by jansari on 2021-09-24 19:57)

Dear All,

As I am working in In vitro laboratory. And we are doing In-vitro binding study on Sevelamer carbonate sachets for EMA submission.


My question is, whether EMA will accepts the In-vitro phosphate binding studies for generic submission like US. Is there any specific guidance documents for statistical analysis of Sevelamer carbonate for EMA Submission or can we perform statistical analysis as per USFDA guidance documents?

And if we perform statistical analysis as per USFDA guidance documents(Acceptance limit for K2-80% to 120%) is it acceptable for EU submission? Is there any acceptance limit for Sevelamer carbonate product for EMA submission?

A response will be highly appreciated.

Thanks in advance for your help.


Regards,
APJ

Complete thread:

UA Flag
Activity
 Admin contact
22,108 posts in 4,630 threads, 1,567 registered users;
online 9 (0 registered, 9 guests [including 4 identified bots]).
Forum time: Friday 15:15 CEST (Europe/Vienna)

We absolutely must leave room for doubt
or there is no progress and no learning.
There is no learning without having to pose a question.
And a question requires doubt.
People search for certainty.
But there is no certainty.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5